Ratings Ion Beam Applications, SA

Equities

IBAB

BE0003766806

Market Closed - Euronext Bruxelles Other stock markets 11:35:13 2024-05-31 am EDT			5-day change	1st Jan Change
14.38 ^EUR	-0.55%		+5.74%	+24.61%

May. 02	Ion Beam Applications SA Signs Contract with Yale New Haven Health and Hartford HealthCare to Install Proteus®?One Proton Therapy Solution in Connecticut, US	CI
Mar. 21	Ion Beam Applications SA to Recommend Dividend for 2023	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The company's profit outlook over the next few years is a strong asset.
With regards to fundamentals, the enterprise value to sales ratio is at 0.77 for the current period. Therefore, the company is undervalued.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company benefits from high valuations in earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
ION BEAM APPLICATIONS, SA	+24.61%	455M	B+
THERMO FISHER SCIENTIFIC	+7.01%	217B	B
DANAHER CORPORATION	+11.01%	190B	B-
INTUITIVE SURGICAL, INC.	+19.20%	143B	B-
BOSTON SCIENTIFIC CORPORATION	+30.79%	111B	A-
SIEMENS HEALTHINEERS AG	+1.48%	64.59B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.36B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	48.45B	B+
AGILENT TECHNOLOGIES, INC.	-6.20%	38.03B	A
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.61B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes